Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.217,01
1,00%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ContraFect Corporation (CFRX) ContraFect Corporation (CFRX) Notizie

CFRX

ContraFect (CFRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CFRX
DataOraFonteTitoloSimboloCompagnia
14/02/202420:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CFRXContraFect Corporation
15/11/202322:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
03/11/202322:08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CFRXContraFect Corporation
03/11/202305:16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CFRXContraFect Corporation
30/10/202322:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
23/10/202322:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CFRXContraFect Corporation
16/10/202313:30GlobeNewswire Inc.ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyNASDAQ:CFRXContraFect Corporation
25/09/202314:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CFRXContraFect Corporation
19/09/202314:30GlobeNewswire Inc.ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentNASDAQ:CFRXContraFect Corporation
18/09/202313:30GlobeNewswire Inc.ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370NASDAQ:CFRXContraFect Corporation
14/09/202322:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CFRXContraFect Corporation
28/08/202314:00GlobeNewswire Inc.ContraFect to Present at the World Anti-Microbial Resistance Congress 2023NASDAQ:CFRXContraFect Corporation
14/08/202322:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CFRXContraFect Corporation
14/08/202314:30GlobeNewswire Inc.ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
27/06/202314:30GlobeNewswire Inc.ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionNASDAQ:CFRXContraFect Corporation
27/06/202314:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
20/06/202314:59GlobeNewswire Inc.ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
08/06/202322:01GlobeNewswire Inc.ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023NASDAQ:CFRXContraFect Corporation
15/05/202322:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CFRXContraFect Corporation
15/05/202314:00GlobeNewswire Inc.ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
04/05/202312:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CFRXContraFect Corporation
28/04/202322:21Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CFRXContraFect Corporation
26/04/202315:00GlobeNewswire Inc.ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
20/04/202314:30GlobeNewswire Inc.ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
06/04/202314:30GlobeNewswire Inc.ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID MeetingNASDAQ:CFRXContraFect Corporation
03/04/202322:45Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CFRXContraFect Corporation
03/04/202314:30GlobeNewswire Inc.ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
31/03/202322:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CFRXContraFect Corporation
31/03/202314:30GlobeNewswire Inc.ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
02/03/202312:29Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CFRXContraFect Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CFRX

La tua Cronologia

UNSW
VVTETH
VersoView
LSE
56KR
Anz Bank 46
EU
H872T
H872T
BIT
UC2V74
Unicredit Bank
NASDAQ
CLPS
CLPS Incorporation
NASDAQ
FDSPJX
Sabrient Dividend Portfo...
LSE
AICC
Aim Vct2
KOSPI
041650
Sangsin Brake
TSXV
BLCC.P
Bow Lake Capital
NASDAQ
AAZDBXX
Jpmorgan Chase Bank Na P...
LSE
AO52
Citi Fun 24
BOV
LSEG34
London Stock Exchange
NASDAQ
AAZPAXX
Jpmorgan Chase Bank Na P...
LSE
16DT
Anz Bank 42
LSE
17ZV
Sse Secs A
COIN
CRMSNBTC
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network